Bryant Furlow, Author at Cancer Therapy Advisor
Bryant Furlow

Bryant Furlow

Contributing Writer https://www.cancertherapyadvisor.com
Bryant Furlow is a contract medical journalist for the Haymarket Medical Network. He holds a BS in biology (summa cum laude) from the University of New Mexico. He covers radiation oncology, immunotherapy, tumor biology, clinical research and health care policy. Prior to joining Haymarket in 2010, Bryant was a newspaper reporter in New Mexico, where he won awards for public health and investigative journalism. He also reports for The Lancet Oncology news desk.

All articles by Bryant Furlow

Researchers proposed lowering the circulating plasma cell threshold from 20% to 5% for plasma cell l

clonoSEQ and MRD Testing in Multiple Myeloma and ALL

Medicare coverage has been announced for Adaptive Biotechnologies’ clonoSEQ® next-generation sequencing assay for the detection of minimal residual disease (MRD) after treatment for multiple myeloma or B-cell acute lymphoblastic leukemia (ALL) — a key step toward its use for patient care in cancer clinics in the United States.1,2The FDA announced regulatory approval for the assay…

Next post in Multiple Myeloma